XNAS
ANTX
Market cap174mUSD
Oct 08, Last price
4.68USD
1D
-3.51%
1Q
4.00%
IPO
-69.57%
Name
AN2 Therapeutics Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
10.03%
Rev. gr., 5y
%
Revenues
0
Net income
-35m
L-31.46%
CFO
-30m
L-39.43%
Dividend
Jan 11, 20180.65625 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Key people
Eric Easom
Chairman of the Board, President, Chief Executive Officer · since 2024
Lucy Day
Chief Financial Officer · since 2022
Sanjay Chanda
Chief Development Officer · since 2019
Stephen Prior
Chief Strategy Officer · since 2024
Joshua Eizen
Chief Operating Officer, Chief Legal Officer, Corporate Secretary · since 2024
Lead Independent Director · since 2024
Kabeer Aziz
Independent Director · since 2019
Gilbert Marks
Independent Director · since 2020
Patricia Martin
Independent Director · since 2021
Rob Readnour
Independent Director · since 2019
Independent Director · since 2022
Independent Director · since 2021
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||